Silverstein Steven, Yeu Elizabeth, Tauber Joseph, Guillon Michel, Jones Lyndon, Galarreta David, Srinivasan Sruthi, Manoj Venkiteshwar
Silverstein Eye Centers, Kansas City, MO 64133, USA.
Virginia Eye Consultants, Norfolk, VA 23502, USA.
Clin Ophthalmol. 2020 Oct 9;14:3167-3177. doi: 10.2147/OPTH.S263362. eCollection 2020.
To evaluate symptom relief in patients with dry eye disease (DED) following a single drop of propylene glycol-hydroxypropyl guar (PG-HPG) nanoemulsion (Systane Complete) lubricant eye drops.
This was a Phase IV, multicenter, open-label, interventional study in adult patients with DED of aqueous-deficient, evaporative, and mixed subtypes. Patients instilled one drop of PG-HPG in each eye at Day 1. Endpoints included change from baseline in dry eye symptom and soothing sensation scores on Day 1 at 0, 4, and 8 hours post-dose. Symptom scores were assessed on a 0-10 scale (0=no symptoms; 10=worst imaginable symptom). Tolerability of the drop was assessed based on assessment score on Day 1 following instillation for overall cohort and by DED subtype.
A total of 134 patients received treatment (mean age: 56.6 years; female: 75.4%). Median changes from baseline at Day 1 in dry eye symptom scores were -1.0 (95% confidence interval [CI]:-3.0,-1.0), -2.0 (95% CI:-3.0,-2.0), and -2.0 (95% CI:-2.0,-1.0) at 0, 4, and 8 hours respectively. Subgroup analysis showed a median change from baseline in dry eye symptom score of -2 (95% CI:-3.0,-1.0) for aqueous-deficient and evaporative subtypes and -1 (95% CI:-3.0,-1.0) for mixed subtype at 8 hours. Median soothing sensation scores were 3 at 0 and 4 hours and 3.5 at 8 hours, with a range of 0-10. Median (range) tolerability assessment scores were 0 (0-8) for burning sensation, stinging sensation, blurring, and 0 (0-10) for foreign body sensation. Tolerability assessment scores by DED subtype confirmed that the majority of patients reported scores in the range of 0-5 for all components and in all subgroups analyzed.
Our study demonstrated that PG-HPG nanoemulsion provided instant/immediate and sustained symptom relief for 8 hours post-single application and was well tolerated in patients with DED, demonstrated by their responses on each of the assessment scales.
评估单滴丙二醇-羟丙基瓜尔胶(PG-HPG)纳米乳剂(思然全效)润滑滴眼液对干眼症(DED)患者症状缓解的效果。
这是一项IV期、多中心、开放标签的干预性研究,纳入水样液缺乏型、蒸发过强型和混合型DED成年患者。患者在第1天每只眼滴入一滴PG-HPG。观察终点包括给药后第1天0、4和8小时干眼症状和舒缓感觉评分相对于基线的变化。症状评分采用0-10分制(0=无症状;10=可想象到的最严重症状)。根据第1天滴入后总体队列以及DED亚型的评估分数评估滴眼液的耐受性。
共有134例患者接受治疗(平均年龄:56.6岁;女性:75.4%)。第1天干眼症状评分相对于基线的中位数变化在0、4和8小时分别为-1.0(95%置信区间[CI]:-3.0,-1.0)、-2.0(95%CI:-3.0,-2.0)和-2.0(95%CI:-2.0,-1.0)。亚组分析显示,8小时时,水样液缺乏型和蒸发过强型干眼症状评分相对于基线的中位数变化为-2(95%CI:-3.0,-1.0),混合型为-1(95%CI:-3.0,-1.0)。舒缓感觉评分在0和4小时为3,8小时为3.5,范围为0-10。烧灼感、刺痛感、视物模糊的耐受性评估分数中位数(范围)为0(0-8),异物感为0(0-10)。DED亚型的耐受性评估分数证实大多数患者在所有分析的组分和所有亚组中的评分在0-5范围内。
我们的研究表明,PG-HPG纳米乳剂单次应用后能立即/迅速缓解症状并持续8小时,DED患者对其耐受性良好,这在各项评估量表的反应中得到了证明。